Download the Protocol

HMG

HMG helps the body’s natural hormones that control fertility work more effectively. It can support sperm or egg development in studies. It’s a mix of two natural hormones, FSH and LH, used for research on reproductive health, not for general medical use.

Description

• HMG, or human menopausal gonadotropin, is a purified blend of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) extracted from the urine of postmenopausal women.
• It mimics the natural pituitary hormones responsible for follicular maturation in females and spermatogenesis in males.
• Used clinically and in research to study fertility, gonadal function, and hormonal regulation.

How It Works

• Stimulates ovarian follicle growth in females by acting on FSH and LH receptors in the ovaries.
• In males, stimulates Leydig and Sertoli cells to promote testosterone production and sperm maturation.
• Works synergistically with hCG to support ovulation and spermatogenesis.

Documented Effects

• Used in assisted reproductive technology (ART) to induce ovulation and support egg development.
• Improves spermatogenesis and fertility in men with secondary hypogonadism.
• Increases gonadal hormone output (testosterone, estrogen, progesterone) under controlled dosing.

Theoretical Effects

• Potential use in research models of fertility restoration and gonadal axis repair.
• May help maintain reproductive hormone balance when combined with hCG in experimental protocols.
• All non-clinical applications remain investigational.

Pharmacokinetics

• Half-life: Approximately 24–36 hours after subcutaneous injection.
• Time to peak concentration: 8–12 hours post-injection.
• Steady-state: Reached after about 3–5 days of consistent administration.

Duration of Effects

• Hormonal stimulation lasts for 24–48 hours after injection.
• Effects on follicular or testicular activity persist for several days with ongoing use.
• Returns to baseline within a week after discontinuation.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 75 IU of HMG (equal blend of FSH and LH activity)
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 75 IU/mL → 7.5 IU per 10 units (0.1 mL)
  • 2 mL water → 37.5 IU/mL → 3.75 IU per 10 units
• Example: Add 1 mL of bacteriostatic water to make 1 IU = ~1.33 units (approximate). Draw 7.5 IU = 10 units.
• Swirl gently to dissolve; do not shake.
• Refrigerate reconstituted solution (2–8 °C). Use within ~10 days for best stability.

Injectable Dosage Overview (Research/Clinical Reference)

Typical Starting Dose

• Females (ovulation studies): 75–150 IU intramuscular (IM) or subcutaneous (SC) daily until follicular maturation.
• Males (fertility studies): 75–150 IU SC three times weekly, often in combination with hCG.

Common Research Range

• 75–300 IU daily depending on research objective and hormonal response.
• For male studies, may combine with 1,000–2,000 IU hCG several times per week.

Maximum Research Range

• Up to 450 IU daily under laboratory monitoring (clinical equivalent for refractory infertility).
• Higher doses increase risk of ovarian hyperstimulation or testicular desensitization.

Standard Cycle Length

• Female research cycles: 7–14 days of HMG administration followed by an ovulation trigger (e.g., hCG).
• Male research cycles: 8–12 weeks for evaluation of spermatogenic response.

Clinical Notes

• Injected subcutaneously or intramuscularly using insulin or standard syringes.
• For males, often alternated with hCG to avoid receptor desensitization.
• For females, treatment typically ends with an ovulation trigger once follicle maturity is reached.
• Stable for about 10 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes

• Possible effects: abdominal bloating, mild injection-site pain, or hormone-related mood changes.
• Monitor estradiol and gonadal hormone levels to avoid overstimulation.
• Intended for controlled research or clinical protocols; not for unsupervised human use.